Travere Therapeutics

• Mirum to acquire all of Travere’s rights and assets related to Cholbam® and Chenodal® • Travere to receive up to $445 million with $210 million upfront and up to $235 million in…

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present nine abstracts, including the…

<!-- Name:DistributionId Value:8829311 --> <!-- Name:EnableQuoteCarouselOnPnr Value:True -->…

<!-- Name:DistributionId Value:8797127 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8752075 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

SAN DIEGO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2022, the Compensation Committee of its Board of Directors…

PDUFA target action date for NDA for sparsentan in IgAN on-track for November 17, 2022 Company to utilize traditional approval process for sparsentan in FSGS following completion of the…

SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present data from the ongoing Phase 1/2 COMPOSE Study of…